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Abstract: The advent of multidrug resistance among pathogenic bacteria is imperiling the worth 
of antibiotics, which have previously transformed medical sciences. The crisis of antimicrobial 
resistance has been ascribed to the misuse of these agents and due to unavailability of newer 
drugs attributable to exigent regulatory requirements and reduced financial inducements. Com-
prehensive efforts are needed to minimize the pace of resistance by studying emergent micro-
organisms, resistance mechanisms, and antimicrobial agents. Multidisciplinary approaches are 
required across health care settings as well as environment and agriculture sectors. Progressive 
alternate approaches including probiotics, antibodies, and vaccines have shown promising results 
in trials that suggest the role of these alternatives as preventive or adjunct therapies in future.
Keywords: antibiotics, multidrug resistance, evolution, alternative therapies
Introduction
Antibiotic resistance is ancient and the “resistome” is a dynamic and mounting prob-
lem. Causes of the global resistome are overpopulation, enhanced global migration, 
increased use of antibiotics in clinics and animal production, selection pressure, poor 
sanitation, wildlife spread, and poor sewerage disposal system.1,2 Antibiotic treatment 
is one of the main approaches of modern medicine which is used to combat infections. 
The “golden era” of antibiotics ranged from the 1930s to 1960s which gave rise to many 
antibiotics.3 Unfortunately, this era ended because researchers were unable to maintain 
the pace of antibiotic discovery in the face of emerging resistant pathogens. Persistent 
failure to develop or discover new antibiotics and nonjudicious use of antibiotics are 
the predisposing factors associated with the emergence of antibiotic resistance.4
Antimicrobial resistance (AMR) poses a serious global threat of growing concern 
to human, animal, and environment health. This is due to the emergence, spread, 
and persistence of multidrug-resistant (MDR) bacteria or “superbugs.”5 MDR bac-
teria exist across the animal, human, and environment triangle or niche and there is 
 interlinked sharing of these pathogens in this triad. The plausible causes of “the global 
resistome” or AMR include excessive use of antibiotics in animals (food, pets, aquatic) 
and humans, antibiotics sold over-the-counter, increased international travel, poor 
sanitation/hygiene, and release of nonmetabolized antibiotics or their residues into 
the environment through manure/feces. These factors contribute to genetic selection 
pressure for the emergence of MDR bacterial infections in the community. Recently, 
the global consumption of antimicrobials in livestock has indicated the hotspots of 
antibiotics use across the continents that will have economic and public health impacts 
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in the years to come. In food animals, antibiotics are com-
monly used in cattle, chicken, and pigs and it is projected 
that in 2030 such use will increase up to 67% in the most 
populated countries of the world.6
The effective use of an antimicrobial agent is undermined 
due to the possible tolerance or resistance developed from 
the very initial time this compound is used. This is true for 
antimicrobial agents used to treat bacterial, viral, fungal, 
and parasitic infections. Several physiological and bio-
chemical mechanisms may steer this developing resistance. 
The intricacy of all the mechanisms associated with the 
emergence and distribution of the resistance should not be 
overplayed. Furthermore, lack of elementary data on these 
specific subjects is a vital concern, which has caused a lack 
of significant achievements from being made to manage the 
development of resistance. Worldwide, various institutes and 
agencies have recognized this serious global public health 
problem. Many recommendations and resolutions have been 
proposed, several reports have also been written, but so far 
little progress has been made. Unfortunately, the increase in 
antibiotic resistance is a persistent issue.7
The discovery of antibiotics was a defining moment in 
the history of mankind that revolutionized medicine and 
saved countless lives. Unfortunately, these “magic bullets” 
have been accompanied by these emerging resistant strains 
of pathogens. Currently, medical experts are raising real con-
cern for a return to the preantibiotic age. After the analysis of 
the available bacterial genomes, it has been concluded that 
over 20,000 potential resistance genes (r genes) are present, 
fortunately; however, the functional resistance determinants 
in various microbes are far less in number.5
During the late 1950s and early 1960s, antibiotic resistance 
to multiple antimicrobial agents was detected, for the very first 
time, among enteric bacteria namely Salmonella, Shigella, and 
Escherichia coli. These resistant strains caused huge clinical, 
economic losses and loss of life, mainly in the developing 
world. However, in the developed world it was considered 
a mild health problem restricted to enteric microbes. This 
misconception changed in the 1970s when it was observed 
that Neisseria gonorrhoeae and Haemophilus influenzae are 
resistant to ampicillin, while in the case of Haemophilus it was 
further reported to resist tetracycline and chloramphenicol as 
well. Due to the increasing use of antimicrobials, the incidence 
of resistance accelerated, particularly in the developing world 
where these drugs were freely accessible without any prescrip-
tion. Deprived hygiene settings facilitated the transmission of 
resistance and insignificant health care funds limited access 
to novel and effective antibiotics.8
Numerous important organizations, like the Centers for 
Disease Control and Prevention (CDC), Infectious Diseases 
Society of America, World Economic Forum, and the World 
Health Organization (WHO) have declared antibiotic resis-
tance to be a “global public health concern.”9,10 The World 
Health Assembly requested WHO to propose a global action 
plan to fight the antibiotic resistance problem.11 Another 
valuable input to the issue has been the recent publication 
of a book titled “The evolving threat of antimicrobial resis-
tance – options for action.” In the UK, people voted for a 
government-sponsored prize of £10 million (Longitude Prize 
challenge) to create novel solutions in combating antibiotic 
resistance.12,13 In America, by 2015, President Barack Obama 
under the recommendations of the US President’s Council of 
Advisors on Science and Technology ordered the National 
Security Council to draft a comprehensive national action 
plan to tackle antibiotic resistance.14,15
Global antibiotic resistance shows no signs of decline, 
though it may perhaps shift direction. The etiology of antibi-
otic resistance is multifaceted, and its consequences pose an 
impact across the globe. Numerous attempts have been made 
to delineate the diverse aspects of antibiotic resistance and 
possible solutions required to deal with this global challenge 
have been tried. However, a principally coordinated campaign 
is lacking, particularly at the political level worldwide.16 Anti-
biotics played an unprecedented role in social and medical 
development, and at present, antibiotics are obligatory in all 
health care systems. The success of modernized medicine, 
namely organ transplantation, cancer therapy, management 
of preterm babies, or a surplus of advanced major surgeries, 
might not have been possible without effective antibiotic 
treatment to control for bacterial infections. If effective global 
action plans are not adopted soon, then we might encounter 
terrible complications for social, medical, and economic 
prospects. Here, we try to portray the global magnitude, 
major etiologies, and consequences and identify key areas 
that require urgent attention.17
The global economic scenario of 
antibiotic resistance
An estimation of the exact economic impact of resistant 
bacterial infections is still a huge global challenge. In this 
matter, measuring the disease distribution associated with 
antibiotic resistance is a key prerequisite. Antibiotic resistance 
is a substantial economic burden to the whole world. In the 
USA alone, antibiotic-resistant pathogen-associated hospital-
acquired infections (HAIs) cause 99,000 deaths annually. In 
2006, about 50,000 Americans died due to two common HAIs, 
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namely pneumonia and sepsis, costing about $8 billion to the 
US economy.18 Patients with antibiotic-resistant bacterial infec-
tions need to stay in the hospital for at least 13 days, adding 
an additional 8 million hospital days annually. Costs of up to 
$29,000 per patient treated with an antibiotic-resistant bacterial 
infection have been reported. In total, economic losses of about 
$20 billion have been recorded in the US, while losses of about 
$35 billion annually have also been recorded in terms of lost 
productivity due to antibiotic resistance in health care systems.15
According to the analysts of Research and Development 
Corporation, a US nonprofit global organization, a worst-case 
scenario may evolve in the coming future where the world 
might be left without any potent antimicrobial agent to treat 
bacterial infections. In this situation, the global economic bur-
den would be about $120 trillion ($3 trillion per annum), which 
is approximately equal to the total existing annual budget of 
the US health care. In general, the world population would be 
hugely affected: as of the year 2050, about 444 million people 
would succumb to infections and birthrates would rapidly 
decline in this scenario.19,20 These losses are calamitous, but 
due to data constraints like the inclusion of overall conditions 
and diseases susceptible to resistance these figures represent 
incomplete images of the economic costs of antibiotic resis-
tance. Another very significant trait of AMR that was absent in 
the investigation is the use of antibiotics in livestock and food 
industry. It is an active participant in the increasing AMR and 
possibly brings its own expected economic losses. A malprac-
tice of the use of antimicrobials as growth promoters is also 
found in many developing countries. Since 2006, this practice 
has been banned in the European Union.21,22
Current estimates of resistance-related costs have lim-
ited scope and do not consider the broader social values 
of antibiotics. These are predisposing factors which steer 
inaccuracy in the estimation of the actual economic burden 
that the world is facing due to this issue. To get the precise 
estimation of the economic ramifications caused, prospec-
tive studies should employ macroeconomic methods, which 
consider all the effects of escalating antibiotic resistance 
especially the reduction in effectiveness of various antibiotics 
in modernized medicine. Until we address these issues, the 
exact estimate of the global economic burden of antibiotic 
resistance may not be fully calculated.15,23
Antibiotic discovery and supremacy
In various parts of the world, from Greece to China, control 
of microbial infection has been well documented in the past. 
In 1928, the discovery of penicillin opened the door to the 
modern era of medicine. Ever since these “magic bullets” 
have transformed medicine and saved countless lives. In the 
1940s, the very first prescription of antibiotics was made. 
During World War II, penicillin was considered as the drug 
of choice and used to control bacterial infections among the 
armed forces.24,25 Unfortunately, soon after that resistance 
against penicillin turned out to be a significant clinical con-
cern. So, most of the advancements made in the 1940s were 
threatened during the 1950s. However, to maintain the use of 
antibiotic treatment strategies, scientists soon discovered and 
developed novel β-lactam antibiotics. Howbeit, the first case 
of methicillin-resistant Staphylococcus aureus (MRSA) was 
reported in the UK and the US in 1962 and 1968, respectively, 
the same decade when new antibiotics were applied.24,26
Regrettably, with the passage of time, resistance has been 
observed to almost all the antibiotics developed during that 
period. Later in 1972, an antibiotic called “vancomycin” 
was presented to the clinicians to treat MRSA.24 During 
that period, it was believed that development of vancomycin 
resistance was unlikely to occur in clinical settings. However, 
during the late 1970s and early 1980s few cases of coagulase-
negative vancomycin-resistant staphylococci were reported. 
Until the early 1980s, the pharmaceutical industry developed 
and introduced many new antibiotics to resolve the resistance 
issue, and with the passage of time, the pace of antibiotic 
development staggered, so very few new antibiotics were 
introduced. Consequently in 2015, after ~70 years since the 
first patient was treated with antibiotic, bacterial infection 
became a serious threat to life once again.24,26
Although at present antibiotic resistance emerges as a 
global threat, there are certain breakthroughs antibiotics have 
handed to humankind, especially in medicine and surgery. 
Antibiotics have treated or prevented bacterial infections 
that may occur during chemotherapy or major surgeries 
like joint replacement, organ transplant, or cardiac surgery. 
These magic bullets have also changed the outcome of bacte-
rial infections which extended the average life expectancy. 
During 1920, expected life spans were 56.4 years in the US; 
on the other hand, at present, the average life span in the 
US is about 80 years. Antibiotics have had a parallel useful 
impact across the globe, such as in the developing world with 
deprived public health infrastructure, as antibiotics reduce the 
morbidity and mortality rate caused by bacterial infections 
in humans and livestock alike.8,25,27
The emergence of antibiotic 
resistance
Microorganisms underwent Darwinian selection to develop 
some stringent mechanisms to escape the lethal effects of 
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antimicrobial substances. Naturally, most of the antibiotics 
are produced by microbes like saprophytic bacteria or envi-
ronmental fungi, others are modified synthetic antibiotics, 
whereas a few are completely synthetic like fluoroquinolones 
and sulphonamides.28 Various organisms evolved defensive 
phenomena against them such as alterations in the target 
site, inhibition of drug entry or distribution, and enzyme 
production that may degrade the antimicrobials. For that 
reason, antibiotic resistance may simply depict the Darwin-
ian competition from natural microbial-derived antimicro-
bial elements.29,30 The functional meta-genomic analysis of 
soil microbes has revealed an extensive diversity in genetic 
determinants associated with antibiotic resistance. Although 
very little has been reported in human pathogens about this 
aspect, production of enzymes (β-lactamases) is an excep-
tional example as a naturally present resistance mechanism 
and has an impact on human health.31,32
It is considered that various antimicrobial molecules 
produced by saprophytic bacteria impede the growth of other 
organisms present in that environment, a mutual benefit in 
such environmental settings, although few findings proposed 
a more complicated interaction. Primarily, it is suggested 
that the concentration of antimicrobial substances in the soil 
appears much lower, and may not be able to inhibit the growth 
of neighboring bacteria.28,29 Second, available data suggest 
that antimicrobial substances with sublethal concentrations 
have a significant impact on microbial physiology, microbial 
evolution, and they may act as effective signaling molecules 
which may induce host or microbial gene expression.32–34 
Another important query is that few saprophytic bacteria 
produce a vital type of broad spectrum antibiotic known as 
carbapenems. Various genes involved in carbapenems syn-
thesis may also play a part in biofilm formation or quorum 
sensing. These findings introduce more queries about the 
unexpected impacts of these antibiotics. This emergence 
of resistance is not limited to natural antimicrobials only, it 
occurs against synthetic antimicrobials too.33
Causes of antibiotic resistance
At present, the multifaceted etiology of antibiotic resistance 
has many factors which are at play. These include inadequate 
regulations and usage imprecisions, awareness deficiency in 
best practices which steers undue or inept use of antibiotics, 
use of antibiotics as a poultry and livestock growth promoter 
rather than to control infection, and online marketing which 
made the unrestricted availability of low-grade antibiotics 
very accessible.20,26
Primarily, overuse of antibiotics is the principal cause of 
resistance evolution, as it was also warned by Sir Alexander 
Fleming that “public will demand [the drug and] then will 
begin an era … of abuses.” Antibiotics kill sensitive bacteria 
but allow resistant pathogens to remain which then reproduce 
and thrive through natural selection. Although overuse of 
antibiotics is strongly discouraged, there remains overpre-
scription across the globe. Several studies have revealed that 
treatment indications, agent choice, and antibiotic therapy 
duration are inappropriate in 30%–50% of the cases.15,35,36 
Globally, antibiotics are used as a growth promoter in live-
stock. According to an estimate, about 80% of the antibiotics 
are sold in the US only for use as growth supplements and to 
control infection in animals. In another study, a global map 
of 228 countries was drawn which depicted the consumption 
of antibiotics in livestock; it was estimated that the total anti-
biotic consumption was 63,151 tons in 2010.6 van Boeckel 
et al have also projected a 67% rise in antibiotic consumption 
by 2030 that would approximately double in Brazil, Russia, 
India, China, and South Africa block of the rapidly develop-
ing and highly populated countries of the world.6
Drivers of antibiotic resistance 
transmission
At present, the understanding of various drivers of antibiotic 
resistance is the key to addressing this global concern. The 
occurrence of resistance in microbes is a natural process 
(Figure 1); until now, antibiotic resistance selection is driven 
using different antibiotics in health care systems, environ-
ment, and in agriculture/livestock. Additional important fac-
tors which are potent drivers of antibiotic resistance include 
sanitation settings, infection control standards, water hygiene 
systems, drug quality, diagnostics and therapeutics, and 
travel or migration quarantine. In addition to the mutation 
in various genes residing on the chromosome of the micro-
organism, exchange of genetic material between organisms 
plays a vital role in the distribution of antibiotic resistance.28 
Plasmid transmission is the most important phenomenon 
which may transfer genes of antibiotic resistance to the host 
cell. Antibiotics may influence this process by inducing the 
transmission of resistance elements; these antimicrobials may 
additionally exert a selective pressure to the emergence of 
resistance.37,38 Demonstration of transmission dynamics of 
resistance has increased the awareness and understanding of 
how resistant pathogens transmit from human to human.17 At 
the community level, feco–oral route is the most important 
route of transmission especially for resistant pathogens of the 
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family Enterobacteriaceae, usually due to sanitation failure. 
Community-acquired (CA)-MRSA is also a good example 
to understand the transmission dynamics of resistance at 
the human–human level, which is usually transmitted due 
to prolonged hospital stay or unhygienic hospital settings. 
Sexual contact is also a source of transmission for resistant 
N. gonorrhoeae.39–41
Another very important facet known as “one health” 
also plays a significant role in the transmission dynamics of 
antibiotic resistance.28 Irrational use of antimicrobial growth 
promoters in farm animals is associated with the transmis-
sion of resistance to humans via animal products; important 
pathogens under consideration in this aspect are Salmonella 
spp. and Campylobacter spp. Additionally, indistinguishable 
resistant mechanisms have been found in bacteria isolated 
from humans or animals. Resistant bacteria and mobile 
genetic elements (MGEs) may make their way from animals 
to humans through various means.42–44 The influence of the 
environment toward antibiotic resistance is also a concern. 
In the agriculture sector, metals are used as microbicides 
and may contribute critically to resistance development. The 
role of sewage systems, pharmaceutical industry pollution, 
and waste management procedures in human–environment 
transmission are also well documented. A number of resistant 
pathogens have been isolated from pre- and posttreatment 
sewage systems.39,45
Superbugs and superresistance
The word “superbugs” denotes microbes with higher morbid-
ity and mortality rate increased due to several mutations pro-
viding resistance to various classes of antibiotics. Therapeutic 
preferences for these resistant microbes are less, and these 
are associated with a prolonged stay at hospital and increased 
economic cost. In certain cases, superresistant strains have 
developed increased virulence and improved transmissibility 
as well.5 Due to aberrant use of antibiotics, numerous bacte-
rial human pathogens have evolved into MDR types. MDR 
Mycobacterium tuberculosis is a prominent example from 
Figure 1 Drivers of antibiotic resistance transmission.
Resistance gene(s)
Transduction
Viral genome
Bacterial chromosome
Plasmid
Conjugation
Origin of mutations to evolve in
changing environment
Bacterial chromosome
Transformation
Possible mobility of mobile genetic elements
(including transposons/integrons)
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both the developing and the developed world.46,47 Other severe 
bacterial infections include Acinetobacter, Burkholderia, 
Campylobacter, Citrobacter, Clostridium, Enterobacter spp., 
Enterococcus, E. coli, Haemophilus, Klebsiella, Proteus, 
Pseudomonas, Salmonella, Serratia, S. aureus, Staphylococ-
cus epidermidis, and Streptococcus pneumoniae.5
S. aureus is considered as the most notorious superbug. It 
is a nasal commensal of humans and can cause common skin 
infections. At present, CA-MRSA with increased acquired 
virulence has emerged as a major community concern. 
Although most of the CA-MRSA properties are similar to 
MRSA, CA-MRSA has some additional characteristics as 
well such as different mec gene clusters and genes encoding 
the cytotoxic Panton–Valentine leukocidin.48,49
Antibiotic resistance and virulence
Bacteria reside on human skin, mucous membrane, and inside 
the human body as well. Among these, bacteria include harm-
less organisms, many of them are useful commensals, and 
few are even essential. However, some are known pathogens 
which cause infection; these are competent enough to colo-
nize, invade, and harm the host tissue.50 Pathogenicity is the 
ability of a bacterium to cause disease, and a pathogen carries 
a number of factors that facilitate the bacterium to increase 
their degree of pathogenicity known as virulence. The most 
important properties which help a pathogen to cause a dis-
ease include toxicity and invasiveness. The ultimate sense of 
balance of a bacterial disease course may be influenced by 
virulence and the host immune status. Both host and bacteria 
have coevolved with time, which may be as long as millions 
of years. Pathogens have amended virulence to get used to 
the immune system of the host during this time period.51 This 
is contrary to the evolution of antibiotic resistance which is a 
relatively recent occurrence mostly in the past five decades 
after the discovery of antibiotics. It is therefore believed that 
resistance and virulence have evolved during different eras.52
Regardless of evolutionary differences, these processes 
share common features, and both processes are indispens-
able for the survival of bacteria under adverse environments. 
Antibiotic resistance enables bacteria able to overcome 
therapeutics and virulence is necessary to fight the host 
immune system.51,53 Second, horizontal gene transfer is the 
mechanism which both resistance and virulence factors use 
to transmit the determinants between genera or species. 
Although other mechanisms like adaptive or compensatory 
mutations may play their role, the transfer of MGEs might 
be the key genetic procedure for distribution and coselection 
of resistance and virulence genes.54,55 Thirdly, in the case of 
intracellular or biofilm producing bacteria, antibiotic resis-
tance is also linked to virulence.56,57 Additionally, various 
properties common to resistance and virulence include cell 
wall modifications, porins (Figure 2), the direct contribution 
of efflux pumps, and two-component systems that stimulate 
or inhibit the gene expression involved in virulence and 
resistance.58–60
MDR opportunistic pathogens like Acinetobacter bau-
mannii and Pseudomonas aeruginosa may grow in niches 
with high antibiotic pressure where several other bacteria may 
not be able to survive and these pathogens may dislocate the 
host microbiota as well. This is an example of how antibiotic 
resistance may improve the virulence or pathogenicity of such 
pathogens and make these bacteria be able to survive in such 
niches. Therefore, antibiotic resistance might be considered 
as a virulence factor, particularly in the case of hospital set-
tings where drug-resistant opportunistic bacteria may cause 
high morbidity and mortality.61,62
Molecular insights of antibiotic 
resistance
In the past two decades, acquired MDR infections have 
increased due to the production of β-lactamases (eg, extended 
spectrum β-lactamases [ESBLs] enzymes, carbapenemases, 
and metallo-β-lactamases), leading to third generation cepha-
losporin and carbapenem resistance.63 Among 21 known 
AMR genes, the important genes responsible for MDR 
Salmonella and E. coli are AmpC, bla-TEM-1, bla-CTX-
M-15, VIM-1, NDM-1, floR, tetG, and the recent mcr-1 gene 
coding colistin drug resistance.64–66 Different mechanisms of 
resistance are described, and novel transmission vectors and 
genes are identified or characterized on a regular basis. In 
general, bacteria may use two mechanisms for resistance: 
1) intrinsic resistance and 2) acquired resistance.67 The 
ability of a bacterium to resist the action of a specific anti-
biotic due to inherent structural or functional properties is 
known as intrinsic resistance. Pseudomonas displays a very 
good example of intrinsic resistance mechanism, due to the 
absence of a susceptible target site for a particular antibi-
otic. Triclosan which is a broad spectrum biocide especially 
against Gram-positive bacteria and several Gram-negative 
bacteria as well is incapable of preventing the growth of 
Pseudomonas. Initially, it was supposed that active efflux is 
the reason behind this resistance, but recently the presence 
of fabI (insensitive allele) encoding an extra enoyl-acyl 
carrier protein reductase enzyme, which is a target site for 
triclosan, has been reported.68,69 Lipopeptide daptomycin, 
approved in 2003 for clinical practice, is an active drug 
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against  Gram-positive bacteria; however, it is ineffective 
against Gram-negative bacteria. The reason behind this is the 
intrinsic variation in the cytoplasmic membrane composition. 
Since the cytoplasmic membrane of Gram-negative bacteria 
has a lesser proportion of anionic phospholipids as compared 
to Gram-positive bacteria, the efficacy of the Ca2+-mediated 
daptomycin insertion into the cytoplasmic membrane, which 
is necessary for the antibacterial activity of daptomycin, is 
reduced.70 Additionally, some antibacterial compounds are 
unable to cross the outer membrane, also considered as a way 
of intrinsic resistance. In Gram-positive bacteria, vancomycin 
inhibits peptidoglycan crosslinking by targeting d-Ala-d-
Ala peptides while in the case of Gram-negative bacteria, 
vancomycin cannot pass through the outer membrane. By 
using high-throughput tools of high-density genome mutant 
libraries in P. aeruginosa, S. aureus, and E. coli, various genes 
associated with intrinsic resistance to different classes of 
antibiotics like β-lactams, aminoglycosides, and fluoroquino-
lones have been identified in recent times.71,72 As an example, 
inactivation of redundant E. coli genes identified putative 
targets for susceptibility phenotyping, like FabI, SapC, 
RecQ, TrxA (thioredoxin), TrxB (thioredoxin reductase), 
DacA, and the d-Ala-d-Ala carboxypeptidase. Inhibition of 
these genes may significantly stimulate drug activity like 
triclosan, rifampicin, aminoglycosides, nitrofurantoin, and 
some β-lactams.72 In addition to the intrinsic mechanism of 
resistance, bacteria may acquire antibiotic resistance as well. 
Various other mechanisms may also help bacteria to acquire 
resistance including antibiotic efflux or poor drug penetration 
resulting in the reduction of the intracellular concentration 
of antibiotic, modification of the antibiotic target site due to 
posttranslational target modification or genetic mutation of 
the target, and inactivation of the antibiotic by modification 
or hydrolysis.73–76 Plasmid coding colistin-resistant (mcr-1 
dependent) E. coli was first isolated from raw meat, animals, 
and humans in China.77 In Pakistan, mcr-1 harboring E. coli 
was also reported from migratory birds and from human 
clinical isolates. MDR (ESBLs, quinolones) E. coli was 
also reported from poultry farms, wild birds, pigeons, dogs, 
and humans.78
Therapeutic strategies to combat 
antibiotic resistance
Control of infection has long been a serious concern of 
the evolutionary race, regardless of the clinical proof that 
approaches based on small molecule monotherapy are inad-
equate in resistance settings. Assessment of various nominees 
for infection control under developmental process suggests 
that the focus of research would be on discovery and identi-
fication of novels antibiotics. Unfortunately,  bio-therapeutics 
Figure 2 Various mechanisms of antibiotic resistance, including drug efflux with the help of efflux pump, enzymatic modifications of the antibiotic, enzymatic breakdown of 
the antibiotics, and modification in the target sites.
Efflux pump
Antibiotic degrading
enzymes
Plasmid
Antibiotic modifying
enzymes
3. Enzymatic breakdown
of antibiotics
2. Enzymatic modifications
of antibiotics
4. Modification in
target site
1. Drug efflux
Bacterial cell wall
Bacterial
chromosome
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like antibiotics, novel combination remedies, and drug 
delivery procedures still lag behind the production of novel 
small molecules that are usually an extension of the present 
drug classes.79 Approaches of systemic monotherapy where 
resistance has overtaken drug development are inadequate 
worldwide. Therefore, instead of combating bacterial evolu-
tion, control strategies might serve better by pursuing resis-
tance mechanisms based on genetic inspiration, for example, 
furanones deployed by red sea algae to disturb the quorum 
sensing of resistant bacteria.80–82
Though the role of biologics in the control of bacterial 
infection is in its infancy, its potential to combat MDR can-
not be overlooked. Small molecules would always have a 
key role in the control of infection; however, on the basis 
of biological inspiration the search for an effective drug 
candidate may possibly be pursued more logistically.79,83 
Various tools used for drug development are essential to 
handle the shortcomings of biologics, like controlled delivery 
options, partial in vitro stability, inadequate high-throughput, 
advanced screening tools, inefficient pharmacokinetics, and 
comparatively unknown pharmacodynamics, and are not as 
radical as those accessible for the development of small mol-
ecules. By chance, a vast potential subsists between biologics 
combinations, molecules based on biological inspiration, 
and drug delivery tools.84,85 Therefore, a paradigm shift like 
cancer and complex viruses might be adapted to eradicate 
susceptible bacteria, handle antibiotic resistance, and shield 
the host microbiota. This type of approach may be crafted 
through the combination of conventional antibiotics, novel 
adjuvants, and viable limited delivery strategies. In contrast 
to various expensive development models which often fail 
in trials, advanced bioinformatics to determine effective 
combination delivery and new targets will possibly bring 
substantial benefits.86
Implementation of various methods of antibiotic resis-
tance is very significant, as it has a substantial impact on 
humans and livestock. Although the resolutions have been 
anticipated, with few being thrown to tackle the crisis, to date 
very little action has been taken toward these solutions.15,87 
At present, antibiotics are obligatory in health settings, and 
the economic, social, and medical costs would be calamitous 
due to disorganized effort. In the face of rising antibiotic 
resistance, the antibiotic efficacy looks increasingly bleak. 
Epidemiological trends in MDR bacteria must be considered 
in developing treatment strategies for infection control. 
Optimistically, constant highlighting of the problem would 
encourage researchers to adopt novel strategies to control 
bacterial infection with the following criteria: discovery of 
novel antibiotics, anticipation and prevention of antibiotic 
resistance, and protection of host microbiota. Preeminent 
approaches that come across with this criterion would help the 
formation of novel combination strategies together with smart 
and local delivery tools, for example, directed nanoparticles, 
liposomes, and infection-responsive polymer-controlled 
delivery. Alternative approaches to antibiotics that are pres-
ently in clinical trials are listed in Table 1.
The use of nanotechnology is emerging in medicine and 
it is not astounding to see these technologies being applied 
for the management of the antibiotic resistance menace. 
Nanoparticles can be utilized for the therapeutic manage-
ment of infections in different ways. They can be coupled 
with existing antimicrobial agents for enhancement of their 
 physiochemical behavior against drug-resistant microbes. 
Second, the colloidal forms of zinc, silver, copper, and tita-
nium can itself be used as antimicrobial agents. Although 
the principal targets of antibiotics include the inhibition or 
disruption of bacterial cell wall, inhibition of proteins, and 
nucleic acids synthesis, nanoparticles are reported to affect 
the respiration system and thereby generation of reactive 
oxygen species that ultimately leads to bacterial death. 
Nanoparticles also target the bacterial cell wall; therefore, 
for example, silver nanoparticles can be coupled with the 
relevant antibiotics to enhance their antibacterial action 
through synergy.88,89
Antimicrobial peptides (AMPs) are emerging antimicro-
bial agents found in animals, microorganisms, and plants and 
have a broader spectrum especially active against different 
bacteria, fungi, and protozoans. The amphipathic nature of 
AMPs enables interaction and insertion into the cell wall and 
cellular membranes of microbes.90 Although AMPs usually 
demonstrate antimicrobial activity because of damage to the 
cellular membranes, they can targets other proteins, DNA, 
RNA, and regulatory enzymes and therefore seem to be a 
promising substitute for classical antibiotics.91–95 However, 
the development of resistance to AMPs is expected as soon 
as AMPs are used in clinical practice; therefore, it is essential 
to explore molecular mechanisms of their action and better 
understanding of the resistance against these compounds is 
necessary for rational planning of the use of AMPs as an 
alternate to antibiotics.96,97
Global action plan to control the 
menace of antibiotic resistance
The global burden of AMR has no signs of receding, rather 
it piles up the pressure on human and veterinary medicine. 
Akin to global warming, AMR is an ecological calamity of 
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indefinite magnitude and has no apparent way out. Until the 
first decade of the current century, scientists and clinicians 
were not up-to-the-minute about AMR, whereas resistant bac-
teria had been identified before the discovery of  penicillin.98 
Consequently, WHO made a landmark by declaring and 
promoting AMR as a global health concern. The agenda for 
such global health concerns is at the developmental stages; 
for example, a book named “The evolving threat of antimi-
crobial resistance – options for action” is a valuable addition 
to the archive.99
Few countries across the globe reported the control of 
various resistant pathogens especially MRSA, but reasons 
behind the decline in the resistance of these microorganisms 
are disputed. For example, the apparent success to confine 
MRSA attained in the US by practicing various schemes 
of hygiene and screenings has been thrown aside because 
some supplementary factors like overall national decline in 
the prevalence of MRSA may be a strong reason of MRSA 
control.100 In Europe, the same actions have also been signifi-
cantly found at the national level. Scientific fraternity must 
appreciate such arguments because we are still struggling to 
recognize the main interventions prerequisite for AMR con-
trol. Perhaps, the eradication of AMR is unattainable but its 
progression may be decelerated.101,102 Different global agen-
cies such as the Global Antimicrobial Resistance Surveillance 
System under WHO should work for the control of antibiotic 
resistance; Food and Agriculture Organization, CDC, and 
Office International des Epizooties  are making strong efforts 
to control antibiotic resistance. Other programs dealing with 
the global threat of antibiotic resistance include the Global 
Health Security Agenda (GHSA), Antimicrobial Resistance 
Action Package (GHSA Action Package Prevent-1).103,104
The fallacy about the enormity and peril of AMR mapped 
the current epidemic. Additionally, studies showing the bur-
den of AMR influenced the think tanks to peruse the issue 
with urgency. Countries that crafted inclusive national plans 
remain successful in controlling AMR. These approaches 
include cautious use of antibiotics, surveillance of antibiot-
ics by employing the “One Health Approach,” advancement 
of health care setup, development of health insurance poli-
cies, restricted drug promotion, consistent disease control 
strategies, and stewardship plans in the community.17 On 
the other hand, these strategies demand patience and time to 
be organized. Furthermore, these require a comprehensive 
endorsement from the government authorities with ample 
funds. In developing countries, progress is at a very low pace, 
Table 1 various product types as alternatives to antibiotics for the therapeutic management of bacterial infections
Target 
bacteria
Product name Product type Company References
Clostridium 
difficile
AmpliPhage-004 Bacteriophages AmpliPhi Biosciences 113
Phenylbutyrate/vitamin D Immune stimulator Akthelia Pharmaceuticals 114, 115
C. difficile toxoid vaccine vaccine Sanofi Pasteur 116
IC84 vaccine valneva 117
NvB302 Antimicrobial peptides Novacta Biosystems 118
AP-114 Antimicrobial peptides Adenium Biotech 119
Bezlotoxumab Antibodies Merck 120, 121
RBX2660 Probiotics Rebiotix 122
SeR-109 Probiotics Seres Therapeutics 123
vP20621 Probiotics viroPharma (Shire) 124
Staphylococcus 
aureus
SA4Ag vaccines Pfizer 125
AP-138 Antimicrobial peptide Adenium Biotech 119
SAL200 Lysins iNtRON Biotechnology 126
CF-301 Lysins ContraFect 127
MeDI4893 Antibodies MedImmune 121, 128
Salvecin Antibodies Aridis Pharmaceuticals 129
514G3 Antibodies XBiotech 130
Pseudomonas 
aeruginosa
AmpliPhage-001 Bacteriophages AmpliPhi Biosciences 131
PT-3.1 Bacteriophages Phico Therapeutics 132
IC43 vaccines valneva 133
Murepavadin Antimicrobial peptides Roche 134
Aerumab Antibodies Aridis Pharmaceuticals 135
Aerucin Antibodies Aridis Pharmaceuticals 136
MeDI3902 Antibodies MedImmune 137
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although some Asian countries including India, in particular, 
have taken some courageous steps toward AMR control in 
recent times, for example, the Chennai declaration.105
Diagnostics pose a significant impact in the setting up of 
AMR because it drives clinicians to use antibiotics impru-
dently. Diagnostics is a pressing issue especially in developing 
countries because they still rely on conventional microbiologi-
cal tools to identify bacteria. These gaps could be bridged by 
developing personalized medicine established based on new 
and efficient molecular diagnostic tools that would be very 
helpful to identify patients who actually need antibiotic therapy. 
One Health Approach could be a very useful tool to study the 
human–animal interface and guide researchers to design novel 
screening tools. This subject is of unique importance and must 
be taken up earnestly because the transmission pathway of 
AMR between all components (human, animal, and environ-
ment) of one health has been established.17,106
Unwise and irrational use of antibiotics is also a salient 
factor associated with AMR especially in low and middle 
income countries (LMICs). Antibiotics are used imprudently 
due to many reasons, such as patient’s contentment over a 
prescription of the physician, inappropriate information 
about antibiotics, improper diagnosis, quackery especially 
in developing countries, and sinfully, temptations of the 
pharmaceutical industry for the physicians. Having a dearth 
of new antibiotics, it is quite difficult to confront this por-
tion of the problem.107 Innovation in antibiotic development, 
combination therapy, and technological development are 
indispensable.108 Another aspect of colossal importance in 
this regard is the integration of the health care system and 
antibiotic stewardships. Data about the impact of AMR on 
health and economy of developing countries are inadequate. 
LMICs have a dire situation in terms of clinical outcomes of 
many fatal bacterial diseases like newborn sepsis, typhoid, 
etc. So, the task is not simply to use conventional options but 
some customized control policies should also be applied; for 
example, resistant pathogens should be prioritized like MDR 
M. tuberculosis. Up to the tertiary level, WHO recommenda-
tions on infection and disease control should be followed. 
Comprehensive data should be collected by taking all the 
national stakeholders including government, academia, and 
industry on board. Additionally, the industry–academia inter-
face should be improved as both academia and industry have 
made some fundamental mistakes in the past. First, in the late 
20th century, academia and researchers had a mistaken belief 
about the elimination of infectious diseases and industry-
produced antibiotics enormously. Second, although financial 
incentives in the form of research grants were provided to 
the academia and pharmaceutical industry, an inadequate 
proportion was allocated to academia and industries for 
the generation of sufficient novel classes of antimicrobial 
agents as compared to the surge of antibiotic resistance.109 In 
atonement, a group of experts named as Infectious Disease 
Society of America submitted a 10×20 plan; this was about 
the development of 10 novel safe and effective antibiotics 
by the end of 2020.110
Use of alternative therapies for the treatment and con-
trol of infectious diseases could also be a different and a 
prolific option to fend off AMR. These therapies include 
anti-virulence strategies (to play with the virulence factors of 
bacteria), biological therapies (use of monoclonal antibodies, 
insulin, erythropoietin, etc), and vaccines (vaccines against 
MRSA, MDR M. tuberculosis).111,112 Moreover, herbal medi-
cines have elusive properties; there is a strong viewpoint that 
it could be a practicable alternate option.
Conclusion
We should seek to increase our knowledge regarding the extent 
of the AMR issue. Comprehensive, unfailing data collection is 
crucial in AMR control. Current angst about this issue is due to 
inadequate information. One cannot predict the future scenario 
with surety at this stage but with the scarcity of novel antibiot-
ics, the control of AMR seems very difficult. Multipronged 
strategies should be adopted to confront this issue. Constant 
and refreshing education of medical students, physicians, and 
pharmacists is required. Regulations should be implemented 
with strict monitoring of antibiotic use as part of the policy. A 
global and interdisciplinary approach must be considered for the 
development of new screening and diagnostic tools. Ecological 
and environmental aspects of the issue need not be ignored; all 
the elements of “one health” should be part and parcel of the 
control policy. Alternative strategies may also play a fruitful 
role, especially in developing countries. Current global interest 
indicates that AMR is not an unheeded issue anymore. Albeit 
this attention is not itself adequate to combat AMR, a global 
code of conducts implementing all the options of action against 
AMR might eliminate AMR in the future. Alternatives to anti-
biotics such as probiotics and lytic bacteriophages can help to 
decrease the burden of AMR globally. The spread and sharing of 
AMR can be contained by the rational use of antibiotics, infec-
tion control, immunization, promoting good practices in food 
supply, and control of person-to-person spread by screening, 
treatment, awareness, and education. At the national, regional, 
and global levels, the tracking, bio-surveillance, and response 
and prevention strategies of AMR and MDR pathogens may 
help to control the “global resistome.”
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